JPH03275630A - Improver for hepatic function and food or beverage for improving hepatic function - Google Patents
Improver for hepatic function and food or beverage for improving hepatic functionInfo
- Publication number
- JPH03275630A JPH03275630A JP2071996A JP7199690A JPH03275630A JP H03275630 A JPH03275630 A JP H03275630A JP 2071996 A JP2071996 A JP 2071996A JP 7199690 A JP7199690 A JP 7199690A JP H03275630 A JPH03275630 A JP H03275630A
- Authority
- JP
- Japan
- Prior art keywords
- protamine
- hepatic function
- liver
- drinking
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003908 liver function Effects 0.000 title claims abstract description 23
- 235000013305 food Nutrition 0.000 title claims abstract description 11
- 235000013361 beverage Nutrition 0.000 title abstract 2
- 102000007327 Protamines Human genes 0.000 claims abstract description 33
- 108010007568 Protamines Proteins 0.000 claims abstract description 33
- 229940048914 protamine Drugs 0.000 claims abstract description 33
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 8
- 239000011707 mineral Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 210000004185 liver Anatomy 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 10
- 108010088751 Albumins Proteins 0.000 abstract description 8
- 102000009027 Albumins Human genes 0.000 abstract description 8
- 229920002527 Glycogen Polymers 0.000 abstract description 7
- 229940096919 glycogen Drugs 0.000 abstract description 7
- 102000004877 Insulin Human genes 0.000 abstract description 5
- 108090001061 Insulin Proteins 0.000 abstract description 5
- 229940125396 insulin Drugs 0.000 abstract description 5
- 235000019688 fish Nutrition 0.000 abstract description 4
- 230000002440 hepatic effect Effects 0.000 abstract description 4
- 241000251468 Actinopterygii Species 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 210000001550 testis Anatomy 0.000 abstract description 3
- 241000972773 Aulopiformes Species 0.000 abstract description 2
- 241000252203 Clupea harengus Species 0.000 abstract description 2
- 235000019514 herring Nutrition 0.000 abstract description 2
- 235000019515 salmon Nutrition 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 2
- 241000269819 Katsuwonus pelamis Species 0.000 abstract 1
- 230000003597 albuminatic effect Effects 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 230000035622 drinking Effects 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 241000700159 Rattus Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004129 EU approved improving agent Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 2
- 108010042606 Tyrosine transaminase Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 244000151012 Allium neapolitanum Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000269959 Xiphias gladius Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000001890 gluconeogenic effect Effects 0.000 description 1
- 235000010784 high vitamin diet Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000021335 sword fish Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野］
本発明は、肝機能改善剤に関する。更に詳しくは飲酒等
によって誘発される肝機能の低下あるいは脂肪肝を予防
するプロタミンより成る肝機能改善剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a liver function improving agent. More specifically, the present invention relates to a liver function-improving agent comprising protamine that prevents a decline in liver function or fatty liver caused by drinking or the like.
［従来の技術］
我国に於ける肝疾患者数は年々増加しており、特にアル
コール性肝障害は、アルコールそのものの毒性と大量飲
酒による低栄養が加わって更に悪化する傾向にある。[Prior Art] The number of people with liver disease in Japan is increasing year by year, and alcoholic liver disease in particular tends to get worse due to the toxicity of alcohol itself and malnutrition caused by heavy drinking.
一般に、長期の飲酒は、摂取エネルギーが十分であって
も蛋白質の摂取量が減少して栄養状態の異常を引き起こ
す。そのほか、内分泌代謝の異常として、インシュリン
分泌の著しい低下を招来する。このインシュリン分泌の
低下によって、肝臓での蛋白質合成が抑制され、その結
果として、脂肪肝が誘発される。In general, long-term drinking causes a decrease in protein intake, leading to abnormal nutritional status, even if energy intake is sufficient. In addition, abnormalities in endocrine metabolism lead to a significant decrease in insulin secretion. This decrease in insulin secretion suppresses protein synthesis in the liver, and as a result, fatty liver is induced.
又、飲酒により、アルブミンの合成が著しく抑制される
と、蛋白質合成に利用されなかったアミノ酸は糖や脂肪
に変換される。従って、アミノ酸の生体内利用において
も好ましくないと考えられる。Furthermore, when albumin synthesis is significantly suppressed by drinking alcohol, amino acids that are not used for protein synthesis are converted into sugars and fats. Therefore, it is considered that it is not preferable for the in vivo utilization of amino acids.
更に、飲酒は、肝グリコーゲン量が、インシュリンの分
泌低下に伴い 減少するため、肝臓機能の抵抗力が弱く
なることから肝疾患を引き起こし易くなる。Furthermore, drinking alcohol reduces the amount of glycogen in the liver due to decreased insulin secretion, weakening the resistance of liver function and making it more likely to cause liver disease.
現在のところ、アルコール性肝疾患の予防及び治療は、
飲酒制限及び高蛋白・高エネルギー・高ビタミン食を基
本とした対症療法に限られている。Currently, prevention and treatment of alcoholic liver disease are
Symptomatic treatment is limited to alcohol restriction and a high-protein, high-energy, high-vitamin diet.
又、アルコール性肝疾患は原因が複雑で多様性を示し、
長期化すると死亡率の高い肝硬変にまで進行するので、
総合的な予防あるいは肝機能改善剤が必要とされている
。In addition, the causes of alcoholic liver disease are complex and diverse;
If prolonged, it can progress to liver cirrhosis, which has a high mortality rate.
Comprehensive prevention or liver function improving agents are needed.
本発明は、飲酒等による肝機能の低下、すなわち、イン
シュリン分泌の低下、血中アルブミン及び肝りリコーゲ
ン量の減少を抑制することを目的とするものである。The purpose of the present invention is to suppress the decline in liver function caused by drinking alcohol, that is, the decline in insulin secretion, and the decrease in blood albumin and liver lycogen levels.
本発明者等は、魚介類精巣中に存在する、アルギニンを
豊富に含有する塩基性蛋白質であるプログよンを標準食
と共にラットに投与すると、飲酒によって低下した肝機
能が回復すること、すなわち、肝機能の指標である血中
インシュリン、アルブミン及び肝グリコーゲン量が正常
値まで回復することを見出した。The present inventors have demonstrated that when Proguyon, a basic protein rich in arginine that is present in the testes of fish and shellfish, is administered to rats along with standard food, liver function decreased by drinking can be restored. It was found that blood insulin, albumin, and liver glycogen levels, which are indicators of liver function, returned to normal values.
本発明はこの知見に基づくものである。従って本発明は
プロタミンより成る肝機能改善剤に係るものである。The present invention is based on this knowledge. Therefore, the present invention relates to a liver function improving agent comprising protamine.
本発明で用いられるプロタミンは、サケ、ニシン、カツ
オ等の魚類精巣から抽出される遊離プロタミン又はプロ
タミン鉱酸塩いずれの形でもよい。The protamine used in the present invention may be in the form of free protamine extracted from the testes of fish such as salmon, herring, and bonito, or in the form of protamine mineral salt.
このプロタミンを、単独で使用するか又は食品又は飲料
等に配合して、肝機能改善剤あるいは肝機能改善効果を
有する食品、飲料等を得る。This protamine is used alone or mixed with foods, drinks, etc. to obtain a liver function improving agent or foods, drinks, etc. having a liver function improving effect.
以上の如きプロタミンより成る肝機能改善剤もしくは肝
機能改善効果を有する食品、飲料等を、プロタミンとし
て５００■／日以下摂取することにより、飲酒等によっ
て低下した肝機能を改善すること、すなわち、肝機能の
指標である血中インシュリン、アルブミン、肝グリコー
ゲン量を正常値まで回復させることができる。By ingesting 500 μg/day or less of liver function improving agents made of protamine or foods, drinks, etc. that have a liver function improving effect as protamine, it is possible to improve liver function decreased due to drinking etc. It is possible to restore blood insulin, albumin, and liver glycogen levels, which are indicators of function, to normal values.
本発明で使用するプロタミンより成る肝機能改善剤の実
施例を以下に示す。Examples of the liver function improving agent comprising protamine used in the present invention are shown below.
実益班−１
５週齢のａＷｉｓｔａｒラットを下記の食餌組成で６週
間飼育した（各群５匹）。Jitsue Group-1 5-week-old aWistar rats were fed for 6 weeks with the following diet composition (5 rats in each group).
表ニー」０４匪底 （ｇ／ｋｇ） 定した。Front knee” 04 bottom (g/kg) Established.
飼育期間中の摂取量、飲酒量、食物効率を表２に、体重
の増加を図１に示す。Table 2 shows the intake, alcohol consumption, and food efficiency during the breeding period, and Figure 1 shows the increase in body weight.
プロタミンの蛋白質含有量ニア０％
照明時間はＡＭ５：００に点燈しＰＨ１：００に消煙し
た。上記組成の食餌をＰＨ１：００から翌日ＡＭ５：０
０の間に摂食させ、この間、飲酒群には１５％ウィスキ
ーを摂食時間帯に飲ませた。Protein content of protamine is near 0% The lighting time was turned on at 5:00 AM and extinguished at 1:00 PH. Feed with the above composition from 1:00 PH to 5:00 AM the next day.
During this period, the drinking group was allowed to drink 15% whiskey during the feeding period.
（結果１）
６週間後、ラットの血中成分、酵素活性等を測飲酒によ
って摂取量が減少し、コントロール群に比べ飲酒群では
食物効率がやや低下した。しかし、飲酒群にプロタミン
を添加しても有意の差は認められなかった。また、飲酒
群において、飲酒量は、無添加床、プロタミン添加区に
おいてほぼ同量であり差が認められなかった。(Result 1) After 6 weeks, blood intake, enzyme activity, etc. of the rats were measured and the intake decreased, and food efficiency was slightly lower in the drinking group compared to the control group. However, no significant difference was observed when protamine was added to the drinking group. Furthermore, in the drinking group, the amount of alcohol consumed was almost the same in the non-additive and protamine-added groups, with no difference observed.
（結果２）
各群の血糖及び血中インシュリンの測定結果を表３に示
す。(Result 2) Table 3 shows the measurement results of blood sugar and blood insulin in each group.
血糖値は、各区間に差は認められなかった。No differences in blood sugar levels were observed between each interval.
血中インシュリン濃度は、飲酒によって低下したが、プ
ロタミン添加区では、正常値に回復した。Blood insulin levels decreased due to drinking alcohol, but returned to normal levels in the protamine-added group.
（”Ｐ＜０．０１ 、 ””Ｐ＜０．００１）（結果３
）
各群の血中総蛋白質・アルブミン量の測定結果を図２に
示す。("P<0.01, ""P<0.001) (Result 3
) Figure 2 shows the measurement results of total blood protein and albumin in each group.
血中総蛋白質・アルブミン量ともに飲酒により有意に減
少したが、プロタミン摂取により正常値まで回復した。Both blood total protein and albumin levels decreased significantly due to drinking alcohol, but they returned to normal values after protamine intake.
（結果４） 各群の肝グリコーゲン量の測定結果を図３に示す。(Result 4) The measurement results of liver glycogen amount in each group are shown in FIG. 3.
飲酒によって肝グリコーゲン量は低下したが、プロタミ
ンの摂取によって正常値まで回復した。Although the amount of hepatic glycogen decreased due to drinking alcohol, it returned to normal levels after taking protamine.
（結果５）
各群の肝・腎糖新生系の酵素活性を測定した結果を表４
に示す。(Result 5) Table 4 shows the results of measuring the enzyme activity of the hepatic and renal gluconeogenic system in each group.
Shown below.
４−の
に番る
（ ′″ ［’＜０．０５ ）
肝グルコース−６−フォスファターゼ（Ｇ−６−Ｐａ５
ｅ ）活性は、飲酒により高まったが、プログくンを摂
取することによって正常値まで回復した。4-Niban ('''['<0.05) Hepatic glucose-6-phosphatase (G-6-Pa5
e) Activity increased due to drinking alcohol, but was restored to normal levels by ingesting Progkun.
また、肝チロシンアミノトランスフェラーゼ（ＴＡＴ）
活性は、飲酒によって低下したが、プロタミンを摂取す
ることによって高まった。In addition, liver tyrosine aminotransferase (TAT)
Activity was decreased by drinking alcohol but increased by taking protamine.
これは、肝臓での飲酒による糖新生の活発化を抑え、大
量に蓄積すると毒性のあるチロシンを分解していること
が分る。This indicates that it suppresses the activation of gluconeogenesis in the liver due to alcohol consumption, and breaks down tyrosine, which is toxic when accumulated in large amounts.
プロタミンを含有する本発明の肝機能改善食品又は飲料
の例を以下に示す。Examples of the liver function improving food or drink of the present invention containing protamine are shown below.
実１自然−」−
下記の原料を使用して、常法により魚肉ソーセージを製
造した。Fruit 1 Natural - Fish sausage was produced using the following raw materials in a conventional manner.
助宗ダラオリ身
太刀魚精肉
グチ精肉
豚脂
ゼラチン
卵白
玉葱
澱粉
植物性蛋白質
調味料
遊離プロタミン
」Ｌ
２６．０
２２．０
１５．０
１０．０
６．０
５．０
１．５
９．０
０．５
４．９
０．１
００
（ソーセージ１本分）
１１逮（−走
図１゜
飲酒ラットの体！増加に及ぼすプロタミンの影響下記の
原料を使用して常法に従って清涼飲料を製造した。Sukemune Daraori Swordfish Meat Crockery Meat Pork Fat Gelatin Egg White Onion Starch Vegetable Protein Seasoning Free Protamine L 26.0 22.0 15.0 10.0 6.0 5.0 1.5 9.0 0.5 4 .9 0.1 00 (for 1 sausage) 11 body movements (-1° body of a drunk rat! Effect of protamine on increase) A soft drink was produced according to a conventional method using the following raw materials.
」Ｌ 果 糖 ６．０ クエン酸 ０．２ グレープフルーツフレーバー ０．２ 遊離プロタミン ０．１ 水 ９３．５ ００ ４、”L Fruit sugar 6.0 citric acid 0.2 grapefruit flavor 0.2 free protamine 0.1 water 93.5 00 4,
図１は飲酒ラッ
トの体重増加に及ぼすプロタミ
ンの影響を示すグラフである。
図２は飲酒ラッ
トの血中総蛋白質量・アルブミ
ン量におけるプロタミンの影響を示すグラフであ重司青
日１Ｂ！（日）
る。
図３は飲酒ラッ
トの肝グリコーゲンにおけるプ
ロタミンの影響を示すグラフである。
図２
飲酒ラットの血中総蛋白質量
タミンの影響
アルフ゛ミン雪におけるプロ
図３
飲酒ラットの肝グリコーゲン１こお１フろプロタミンの
影響口ｋＭ日＠響
１【ア；ン１１
ブＯタミンFIG. 1 is a graph showing the effect of protamine on weight gain in drinking rats. Figure 2 is a graph showing the influence of protamine on total protein and albumin levels in the blood of drinking rats. (Japanese) Ru. FIG. 3 is a graph showing the influence of protamine on liver glycogen in drinking rats. Figure 2 Effect of total protein content in the blood of drinking rats.
Claims (1)
善剤。 ２、プロタミン又はプロタミン鉱酸塩を食品に添加して
なる肝機能改善食品。 ３、プロタミン又はプロタミン鉱酸塩を飲料に添加して
なる肝機能改善飲料。[Claims] 1. A liver function improving agent comprising protamine or protamine mineral salt. 2. A liver function improving food obtained by adding protamine or protamine mineral salt to food. 3. A liver function-improving drink obtained by adding protamine or protamine mineral salt to a drink.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2071996A JPH03275630A (en) | 1990-03-23 | 1990-03-23 | Improver for hepatic function and food or beverage for improving hepatic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2071996A JPH03275630A (en) | 1990-03-23 | 1990-03-23 | Improver for hepatic function and food or beverage for improving hepatic function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03275630A true JPH03275630A (en) | 1991-12-06 |
Family
ID=13476599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2071996A Pending JPH03275630A (en) | 1990-03-23 | 1990-03-23 | Improver for hepatic function and food or beverage for improving hepatic function |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03275630A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1505989A2 (en) * | 2002-05-20 | 2005-02-16 | Cedars-Sinai Medical Center | Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration |
| US9744208B2 (en) | 2013-03-15 | 2017-08-29 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US9845511B2 (en) | 2013-03-15 | 2017-12-19 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US9956292B2 (en) | 2014-08-13 | 2018-05-01 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| US10066254B2 (en) | 2002-05-20 | 2018-09-04 | Cedars-Sinai Medical Center | Diagnosis of constipation by analysis of methane concentration |
| US10736871B2 (en) | 2015-04-01 | 2020-08-11 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
-
1990
- 1990-03-23 JP JP2071996A patent/JPH03275630A/en active Pending
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066254B2 (en) | 2002-05-20 | 2018-09-04 | Cedars-Sinai Medical Center | Diagnosis of constipation by analysis of methane concentration |
| US10844417B2 (en) | 2002-05-20 | 2020-11-24 | Cedars-Sinai Medical Center | Method of distinguishing constipation predominant IBS from inflammatory bowel syndrome by analysis of methane concentration |
| AU2003273141B2 (en) * | 2002-05-20 | 2009-05-07 | Cedars-Sinai Medical Center | Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration |
| EP2251017A1 (en) * | 2002-05-20 | 2010-11-17 | Cedars-Sinai Medical Center | Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration |
| US9066962B2 (en) | 2002-05-20 | 2015-06-30 | Cedars-Sinai Medical Center | Method of using a probiotic microorganism for the treatment of diarrhea |
| US9192618B2 (en) | 2002-05-20 | 2015-11-24 | Cedars-Sinai Medical Center | Method of treating constipation-predominant irritable bowel syndrome |
| US9358245B2 (en) | 2002-05-20 | 2016-06-07 | Cedars-Sinai Medical Center | Method of treating constipation |
| EP1505989A2 (en) * | 2002-05-20 | 2005-02-16 | Cedars-Sinai Medical Center | Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration |
| EP1505989A4 (en) * | 2002-05-20 | 2007-05-09 | Cedars Sinai Medical Center | Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration |
| US9744208B2 (en) | 2013-03-15 | 2017-08-29 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US10226505B2 (en) | 2013-03-15 | 2019-03-12 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US10519515B2 (en) | 2013-03-15 | 2019-12-31 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US10688149B2 (en) | 2013-03-15 | 2020-06-23 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US9845511B2 (en) | 2013-03-15 | 2017-12-19 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US10328151B2 (en) | 2014-08-13 | 2019-06-25 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| US10668159B2 (en) | 2014-08-13 | 2020-06-02 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| US9956292B2 (en) | 2014-08-13 | 2018-05-01 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| US11344501B2 (en) | 2014-08-13 | 2022-05-31 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| US11590102B2 (en) | 2015-04-01 | 2023-02-28 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| US10736871B2 (en) | 2015-04-01 | 2020-08-11 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014009216A (en) | Composition containing peptide and/or free amino acid | |
| Causeret | Fish as a source of mineral nutrition | |
| CA1088425A (en) | Bio-available essential metals | |
| Valdimarsson et al. | World fisheries—utilisation of catches | |
| JP5749880B2 (en) | Body fat accumulation improving agent and metabolic syndrome improving agent comprising D-tagatose as an active ingredient | |
| JP2010018522A (en) | Adiponectin production enhancer | |
| US8663725B2 (en) | Method for deriving a high-protein powder/ omega 3 oil and double distilled water from any kind of fish or animal ( protein) | |
| JPH03275630A (en) | Improver for hepatic function and food or beverage for improving hepatic function | |
| JPWO2007142230A1 (en) | Lipid metabolism improver | |
| Yu et al. | Seasonal variation in the nutritional components and textural properties of Pacific abalone and its hybrids | |
| JP2010104338A (en) | Method for improving taste of collagen-containing food and drink | |
| Godber | Nutritional value of muscle foods | |
| CN100463615C (en) | Preparation method of instant fish ball | |
| JP2008050277A (en) | Composition for treating sideropenic anemia | |
| KR20060030005A (en) | The method for making functional fishes using phellinus linteus and product thereof | |
| JPS60186261A (en) | Solid food composition | |
| JP2001029042A (en) | Edible composition containing natural carnosine | |
| JP3915090B2 (en) | Dietary supplement or beverage composition | |
| JP2002338482A (en) | Insulin-resistance improving agent and food, drink and tablet for improving insulin resistance | |
| JP2952300B2 (en) | Nutrition improving composition and oral nutrition improving agent | |
| JP7369568B2 (en) | Composition for promoting alcohol metabolism | |
| Pepito et al. | Nutritional Quality of the Egg Mass Locally Known as “Lukot’of the Wedge Seahare Dolabella auricularia (Lightfoot, 1786) | |
| JP2002330727A (en) | Food additive composition and method for producing the same | |
| JP6629469B1 (en) | An antihypertensive agent comprising a chondroitin sulfate-containing porcine cartilage extract as an active ingredient and a food composition containing the same | |
| JP2009234984A (en) | Agent for inhibition of lowering or for ameliorating renal function |